MTOR: Taking cues from the immune microenvironment

Immunology

Volumn 127, Issue 4, 2009, Pages 459-465

  Delgoffe, Greg M ^a   Powell, Jonathan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anergy; Dendritic cells; Mammalian target of rapamycin; Regulatory T cell; T cell

Indexed keywords

CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TACROLIMUS;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CLONAL ANERGY; DENDRITIC CELL; ENZYME INHIBITION; IMMUNE RESPONSE; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; CLONAL ANERGY; DENDRITIC CELLS; HUMANS; LYMPHOCYTE ACTIVATION; PROTEIN KINASES; T-LYMPHOCYTES, REGULATORY;

EID: 67650553603     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03125.x     Document Type: Review

References (64)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970 169 : 1042 9.
2. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975 53 : 27 42.
3. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515 48.
4. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006 27 : 195 201.
5. Medzhitov R, Janeway CA Jr. How does the immune system distinguish self from nonself? Semin Immunol 2000 12 : 185 8.
6. Pasare C, Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol 2004 16 : 23 6.
7. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996 8 : 271 80.
8. Matzinger P. The danger model: a renewed sense of self. Science 2002 296 : 301 5.
9. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008 112 : 1557 69.
10. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006 24 : 677 88.
11. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996 14 : 483 510. (Pubitemid 26130192)
12. Jozwiak J, Jozwiak S, Oldak M. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev 2006 26 : 160 80.
13. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006 6 : 729 34.
14. Goberdhan DC, Boyd CA. mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans 2009 37 : 213 6.
15. Harris TE, Lawrence JC Jr. TOR signaling. Sci STKE 2003 2003, re15.
16. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007 17 : 666 81.
17. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004 14 : 1296 302.
18. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005 280 : 40406 16.
19. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005 307 : 1098 101.
20. Franke TF. Intracellular signaling by Akt: bound to be specific. Sci Signaling 2008 1 : pe29.
21. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006 22 : 159 68.
22. Zeng Z, Sarbassov dos D, Samudio IJ et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007 109 : 3509 12.
23. Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992 13 : 69 73.
24. Gilbert KM, Weigle WO. Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol 1993 151 : 1245 54.
25. Vanasek TL, Khoruts A, Zell T, Mueller DL. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol 2001 167 : 5636 44.
26. Wells AD, Walsh MC, Sankaran D, Turka LA. T cell effector function and anergy avoidance are quantitatively linked to cell division. J Immunol 2000 165 : 2432 43.
27. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999 162 : 2775 84.
28. Allen A, Zheng Y, Gardner L, Safford M, Horton MR, Powell JD. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 2004 172 : 4797 803.
29. Colombetti S, Benigni F, Basso V, Mondino A. Clonal anergy is maintained independently of T cell proliferation. J Immunol 2002 169 : 6178 86.
30. Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, Powell JD. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007 178 : 2163 70.
31. Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol 2006 176 : 2730 8.
32. Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2000 164 : 144 51.
33. Powell JD, Bruniquel D, Schwartz RH. TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of p27(Kip1). Eur J Immunol 2001 31 : 3737 46.
34. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969 166 : 753 5.
35. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998 160 : 1212 8.
36. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003 198 : 1875 86.
37. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008 133 : 775 87.
38. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006 177 : 8338 47.
39. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005 105 : 4743 8.
40. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, Ayyoub M. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006 177 : 944 9.
41. Kang J, Huddleston SJ, Fraser JM, Khoruts A. De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 2008 83 : 1230 9.
42. Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, Zeng C, Zhao Y. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+ T cells in mice. Transpl Immunol 2007 17 : 153 61.
43. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007 178 : 320 9.
44. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008 180 : 5794 8.
45. Sauer S, Bruno L, Hertweck A et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008 105 : 7797 802.
46. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008 205 : 565 74.
47. Guertin DA, Stevens DM, Thoreen CC et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006 11 : 859 71.
48. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004 16 : 21 5.
49. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002 99 : 351 8.
50. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, Thomson AW. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003 101 : 4457 63.
51. Turnquist HR, Sumpter TL, Tsung A et al. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol 2008 181 : 62 72.
52. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003 101 : 1439 45.
53. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005 5 : 228 36.
54. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007 178 : 7018 31.
55. Ko H, Hambly BD, Eris JM, Levidiotis V, Wyburn K, Wu H, Chadban SJ, Yin JL. Dendritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transpl Immunol 2008 20 : 99 105.
56. Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008 29 : 565 77.
57. Ohtani M, Nagai S, Kondo S et al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 2008 112 : 635 43.
58. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, Pulendran B. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008 9 : 1157 64.
59. Reichardt W, Durr C, von Elverfeldt D et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol 2008 181 : 4770 9.
60. Sinclair LV, Finlay D, Feijoo C et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008 9 : 513 21.
61. Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 2008 21 : 2 10. (Pubitemid 350198279)
62. Powell JD, Zheng Y. Dissecting the mechanism of T cell anergy with immunophilin ligands. Curr Opin Investig Drugs 2006 7 : 1002 7.
63. Kopf H, de la Rosa GM, Howard OM, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007 7 : 1819 24.
64. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007 12 : 487 502. (Pubitemid 46523652)